Clinical Efficacy of Levosimendan in the Treatment of Chronic Heart Failure and its Effect on Neurohormones,Left Ventricular Remodeling and MicroRNAs
Objective:To investigate the clinical efficacy of levosimendan in the treatment of chronic heart failure(CHF)and its effect on neurohormones,left ventricular remodeling and microRNAs.Methods:A total of 120 CHF patients treated in a hospital from January to December 2022 were selected and assigned to the control group and observation group by random number table method,with 60 patients in each group.The control group was treated with conventional therapy,while the observation group was treated with levosimendan injection in addition to the treatment given in the control group,and both groups were treated for 2 weeks.Neurohormones[aldosterone(ALD),norepinephrine(NE)and angiotensin Ⅱ(Ang Ⅱ)],left ventricular remodeling indexes[mean wall stress(MWS),left ventricular end-diastolic diameter(LVEDD),left ventricular mass index(LVMI),left atrial volume index(LAVI)],microRNAs[microRNA-19b-3p(miR-19b-3p),microRNA-497(miR-497)and microRNA-30a(miR-30a)],clinical response and adverse reactions were compared between the two groups.Results:After treatment,the serum levels of ALD,NE and Ang Ⅱ were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).MWS,LVEDD,LVMI and LAVI were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The serum levels of miR-19b-3p and miR-497 were increased in both groups(P<0.05),and were higher in the observation group than those in the control group(P<0.05).The serum miR-30a level was decreased in both groups(P<0.05),and was lower in the observation group than that in the control group(P<0.05).The total response rate in the observation group(90.00％)was higher than that in the control group(68.33％,P<0.05).No statistically significant difference in the incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:Levosimendan combined with conventional therapy has definite clinical efficacy in the treatment of CHF as demonstrated by effectively improved levels of serum neurohormones and microRNAs and inhibited left ventricular remodeling,without additional risks of adverse reactions.
万方数据
维普
